Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 193-198 , May 2007

Transforming growth factor-beta 1 levels in women with prior history of gestational diabetes mellitus

  • S. Yener

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 2324123716; fax: +90 2322594898
    • ,
  • T. Demir

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey
    • ,
  • B. Akinci

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey
    • ,
  • F. Bayraktar

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey
    • ,
  • L. Kebapcilar

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey
    • ,
  • M.A. Ozcan

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Hematology, Izmir, Turkey
    • ,
  • S. Biberoglu

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey
    • ,
  • S. Yesil

      Affiliations

    • Dokuz Eylul University, School of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Izmir, Turkey

Received 14 July 2006 ,Revised 24 August 2006 ,Accepted 29 August 2006.

References 

  1. Le Y, Yu X, Ruan L, Wang O, Qi D, Zhu J, et al. The immunopharmacological properties of transforming growth factor beta. Int Immunopharmacol. 2005;5:1771–1782
  2. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arteriosc Thromb Vasc Biol. 2004;24(3):399–404
  3. Peterson MC. Circulating transforming growth factor beta-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit. 2005;11(7):RA229–RA232
  4. Laviades C, Varo N, Diez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension. 2000;36(4):517–522
  5. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab. 2003;88:5321–5326
  6. Porreca E, Di Febbo C, Vitacolonna E, Baccante G, Di Castelnuovo A, Angelini A, et al. Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens. 2002;15:759–765
  7. Pfeiffer A, Middelberg-Bisping K, Drewes C, Schatz H, et al. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabet Care. 1996;19:1113–1117
  8. Esmatjes E, Flores L, Lario S, Claria J, Cases A, Inigo P, et al Smoking increases serum levels of transforming growth factor-beta in diabetic patients. Diabet Care. 1999;22:1915–1916
  9. Shankland SJ, Scholey JW, Ly H, Thai K. Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int. 1994;46:430–442
  10. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton). 2005;10(1):48–56
  11. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–1358
  12. Kaufmann RC, Schleyhahn FT, Huffman DG, Amankwah KS. Gestational diabetes diagnostic criteria: long-term maternal follow-up. Am J Obstet Gynecol. 1995;172:621–625
  13. Metzger BE, Cho NH, Roston SM, Radvany R. Prepregnancy weight and antepartum insulin secretion predict glucose tolerance five years after gestational diabetes mellitus. Diabet Care. 1993;16:1598–1605
  14. Heitritter SM, Solomon CG, Mitchell GF, Skali-Ounis N, Seely EW. Subclinical inflammation and vascular dysfunction in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab. 2005;90:3983–3988
  15. Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, et al. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabet Care. 2004;27:1721–1727
  16. Lauenborg J, Mathiesen E, Hansen T, Glumer C, Jorgensen T, Borch-Johnsen K, et al. The prevalence of the metabolic syndrome in a Danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. J Clin Endocrinol Metab. 2005;90:4004–4010
  17. Kousta E, Lawrence NJ, Godsland IF, Penny A, Anyaoku V, Millauer BA, et al. Insulin resistance and beta-cell dysfunction in normoglycaemic European women with a history of gestational diabetes. Clin Endocrinol (Oxf). 2003;59:289–297
  18. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci USA. 1998;95(13):7591–7596
  19. Alessi MC, Bastelica D, Morange P, Berthet B, Leduc I, Verdier M, et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 2000;49:1374–1380
  20. Gottschling-Zeller H, Birgel M, Rohrig K, Hauner H. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture. Metabolism. 2000;49:666–671
  21. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991;88(4):1346–1353
  22. Ghosh J, Murphy MO, Turner N, Khwaja N, Halka A, Kielty CM, et al. The role of transforming growth factor beta1 in the vascular system. Cardiovasc Pathol. 2005;14(1):28–36
  23. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, Masaki T, et al. Transforming growth factor-beta stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun. 1989;159:1435–1440
  24. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med. 1991;114:464–469
  25. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension. 1998;31(1 Pt 2):181–188
  26. Rossert J, Terraz-Durasnel C, Brideau G. Growth factors, cytokines, and renal fibrosis during the course of diabetic nephropathy. Diabet Metab. 2000;26(Suppl 4):16–24
  27. Grant PJ. Inflammatory atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin. 2005;21(Suppl 1):S5–S12
  28. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137–161
  29. McCartney-Francis NL, Frazier-Jessen M, Wahl SM. TGF-beta: a balancing act. Int Rev Immunol. 1998;16(5–6):553–580
  30. Suzumura A, Sawada M, Yamamoto H, Marunouchi T. Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro. J Immunol. 1993;151:2150–2158
  31. Shrikant P, Lee SJ, Kalvakolanu I, Ransohoff RM, Benveniste EN. Stimulus-specific inhibition of intracellular adhesion molecule-1 gene expression by TGF-beta. J Immunol. 1996;157:892–900
  32. Winkler MK, Beveniste EN. Transforming growth factor-beta inhibition of cytokine-induced vascular cell adhesion molecule-1 expression in human astrocytes. Glia. 1998;22(2):171–179
  33. Flores L, Naf S, Hernaez R, Conget I, Gomis R, Esmatjes E. Transforming growth factor beta at clinical onset of Type 1 diabetes mellitus. A pilot study. Diabet Med. 2004;21:818–822
  34. Li Z, et al. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension. 1999;33(1):116–123
  35. Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part III. Cellular and molecular clues to heart and arterial aging. Circulation. 2003;107(3):490–497
  36. Wang M, Lakatta EG. Altered regulation of matrix metalloproteinase-2 in aortic remodeling during aging. Hypertension. 2002;39(4):865–873
  37. Wang M, Zhang J, Spinetti G, Jiang LQ, Monticone R, Zhao D, et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol. 2005;167:1429–1442
  38. Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res. 2005;66:276–285

PII: S0168-8227(06)00382-2

doi: 10.1016/j.diabres.2006.08.014

Diabetes Research and Clinical Practice
Volume 76, Issue 2 , Pages 193-198 , May 2007

Article Tools

* Image Usage & Resolution